Mediators of Inflammation

Mediators of Inflammation / 2014 / Article
Special Issue

Antioxidative Strategy for Inflammatory Diseases

View this Special Issue

Research Article | Open Access

Volume 2014 |Article ID 379537 |

Huang-Joe Wang, Yuan-Li Huang, Ya-Yun Shih, Hsing-Yu Wu, Ching-Tien Peng, Wan-Yu Lo, "MicroRNA-146a Decreases High Glucose/Thrombin-Induced Endothelial Inflammation by Inhibiting NAPDH Oxidase 4 Expression", Mediators of Inflammation, vol. 2014, Article ID 379537, 12 pages, 2014.

MicroRNA-146a Decreases High Glucose/Thrombin-Induced Endothelial Inflammation by Inhibiting NAPDH Oxidase 4 Expression

Academic Editor: Yung-Hsiang Chen
Received23 May 2014
Revised10 Aug 2014
Accepted10 Aug 2014
Published14 Sep 2014


Diabetes is associated with hyperglycemia and increased thrombin production. However, it is unknown whether a combination of high glucose and thrombin can modulate the expression of NAPDH oxidase (Nox) subtypes in human aortic endothelial cells (HAECs). Moreover, we investigated the role of a diabetes-associated microRNA (miR-146a) in a diabetic atherothrombosis model. We showed that high glucose (HG) exerted a synergistic effect with thrombin to induce a 10.69-fold increase in Nox4 mRNA level in HAECs. Increased Nox4 mRNA expression was associated with increased Nox4 protein expression and ROS production. Inflammatory cytokine kit identified that the treatment increased IL-8 and IL-6 levels. Moreover, HG/thrombin treatment caused an 11.43-fold increase of THP-1 adhesion to HAECs. In silico analysis identified the homology between miR-146a and the 3′-untranslated region of the Nox4 mRNA, and a luciferase reporter assay confirmed that the miR-146a mimic bound to this Nox4 regulatory region. Additionally, miR-146a expression was decreased to 58% of that in the control, indicating impaired feedback restraint of HG/thrombin-induced endothelial inflammation. In contrast, miR-146a mimic transfection attenuated HG/thrombin-induced upregulation of Nox4 expression, ROS generation, and inflammatory phenotypes. In conclusion, miR-146a is involved in the regulation of endothelial inflammation via modulation of Nox4 expression in a diabetic atherothrombosis model.

1. Introduction

Diabetes mellitus is an epidemic that affects all age groups worldwide. Both microvascular (nephropathy, neuropathy, and retinopathy) and macrovascular diseases (atherosclerosis of coronary, cerebral, and peripheral arteries) are prevalent in diabetic patients. Diabetes is associated with polyvascular, accelerated, and diffuse atherosclerotic diseases [1]. In advanced stages, the chances of atherosclerotic plaque rupture increase, which can cause atherothrombosis with clinical presentations of acute ischemic stroke, acute myocardial infarction, and peripheral arterial occlusive disease.

Endothelial dysfunction is an initiator of diabetic vascular diseases. Multiple diabetes-associated stresses, including hyperglycemia, impaired insulin signaling, advanced glycated end products, and dyslipidemia, lead to the inflammation of the endothelium, which can lead to thrombosis [2]. These metabolic abnormalities in diabetes increase the generation of reactive oxygen species (ROS), effectors that play a major role in producing a proinflammatory phenotype that culminates into accelerated atherosclerosis and atherothrombosis [3]. The most important ROS-generating systems in the vasculature include the mitochondrial electron transport chain, xanthine oxidase, and NADPH oxidases (Noxes) [2]. Noxes are transmembrane electron transporters that transport the cytoplasmic electron donor NADPH to oxygen in order to generate superoxide. Among the 7 known subtypes, Nox1, Nox2, Nox4, and Nox5 are expressed in endothelial cells and are the major sources of ROS in the cardiovascular systems [4].

MicroRNAs (miRs) are endogenous ~22-nucleotide RNAs that bind to the 3′-untranslated region (UTR) of a messenger RNA (mRNA) target. These miRs can regulate the oxidative and inflammatory state at the posttranscriptional level by causing degradation of the target mRNA or inhibiting translation [5]. Among the many miRs, miR-146a is identified as a negative regulator of NF-κB, which targets IRAK1, TRAF6, and IRAK2 [6, 7]. Generally, an increased level of cellular miR-146a that exerts a negative feedback effect on NF-κB signaling is observed during multiple stresses (e.g., TNF-, LPS, interleukin- (IL-) 1β, PMA, and ox-LDL) [6, 811]. However, decreased cellular miR-146a levels have been reported in multiple diabetes-related studies, including in high glucose- (HG-) stimulated endothelial cells and diabetic rats [12, 13], in diabetic mouse wounds [14], in glycated albumin-stimulated endothelial cells [15], and in type 2 diabetes patients with subclinical inflammation and insulin resistance [16]. All of the above in vitro and in vivo evidences indicate that impaired miR-146a expression contributes to the proinflammatory state in diabetes.

The hallmark of diabetes is hyperglycemia. In addition, diabetes can cause a hypercoagulable state that is due to increased thrombin generation [17, 18]. Since HG and thrombin are known to increase ROS production [19, 20], the present study investigated whether a combination of HG and thrombin (HG/thrombin) influenced Nox subtype expression and endothelial inflammation. In addition, we tested whether miR-146a is involved in the regulation of Nox4 expression in this in vitro model of diabetic atherothrombosis.

2. Materials and Methods

2.1. Cell Culture

Human aortic endothelial cells (HAECs) were purchased from Cell Applications, Inc. (San Diego, CA) and cultured in endothelial cell growth medium (Cell Applications, Inc.) according to the manufacturer’s recommendations. The cells were grown to near confluence in a 75-T flask before the experiment. All chemicals were obtained from Sigma-Aldrich (St. Louis, MO) unless otherwise specified. Thrombin at a dose of 2 units/mL and D-glucose (25 mmol/L) were added to the HAECs for the respective times. L-glucose (25 mmol/L) was used as an osmotic control. The human monocytic cell line THP-1 was obtained from the American Type Culture Collection (Rockville, MD) and maintained in RPMI-1640 culture medium (Thermo Scientific HyClone, Logan, UT) supplemented with 10% FBS and 1% penicillin-streptomycin (Invitrogen, Carlsbald, CA).

2.2. Real-Time Polymerase Chain Reaction (PCR)

The mRNA expression level in the HAECs was analyzed by real-time PCR, as previously described [21]. The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was selected for normalization of data. These real-time PCR data were calculated by the method for RNA quantification. The primer sequences used for the amplification of genes encoding GAPDH, Nox1, Nox2, Nox4, Nox5, interleukin-6 (IL-6), interleukin-8 (IL-8), vascular cell adhesion protein 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), and E-selectin (SELE) were as follows:GAPDH:Forward primer: 5′-CTCTGCTCCTCCTGTTCGAC-3′Reverse primer: 5′-ACGACCAAATCCGTTGACTC-3′Nox1:Forward primer: 5′-TCACCCCCTTTGCTTCTATCT-3′Reverse primer: 5′-AATGCTGCATGACCAACCTT-3′Nox2:Forward primer: 5′-CATTCAACCTCTGCCACCAT-3′Reverse primer: 5′-CCCCAGCCAAACCAGAAT-3′Nox4:Forward primer: 5′-GCTGACGTTGCATGTTTCAG-3′Reverse primer: 5′-CGGGAGGGTGGGTATCTAA-3′Nox5:Forward primer: 5′-GGAGAAGATGAACACATCTGGAG-3′Reverse primer: 5′-CATCCTCCTCGGCACTCA-3′IL-6:Forward primer: 5′-GATGAGTACAAAAGTCCTGATCCA-3′Reverse primer: 5′-CTGCAGCCACTGGTTCTGT-3′IL-8:Forward primer: 5′-AGACAGCAGAGCACACAAGC-3′Reverse primer: 5′-ATGGTTCCTTCCGGTGTT-3′VCAM-1:Forward primer: 5′-TGCACAGTGACTTGTGGACAT-3′Reverse primer: 5′-CCACTCATCTCGATTTCTGGA-3′ICAM-1:Forward primer: 5′-CCTTCCTCACCGTGTACTGG-3′Reverse primer: 5′-AGCGTAGGGTAAGGTTCTTGC-3′SELE:Forward primer: 5′-ACCAGCCCAGGTTGAATG-3′Reverse primer: 5′-GGTTGGACAAGGCTGTGC-3′

2.3. Western Blot Analysis

The protein expression level in the HAECs was analyzed by western blot analysis, as previously described [21]. Antibodies against Nox4 (GeneTex, Irvine, CA) and GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA) were used at concentrations of 1 : 1000 and 1 : 2000, respectively. Whole cell lysates were used in all blots, which were normalized to GAPDH.

2.4. Intracellular ROS Determination

Intracellular ROS expression level was analyzed by an Oxiselect Intracellular ROS Assay Kit (Cell Biolabs, San Diego, CA), which measures ROS by employing the cell-permeable fluorogenic probe 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA). Briefly, HAECs (1 × 104) were stimulated with different stressors for 5 h before determining the level of ROS. The level of ROS was determined according to the manufacturer’s protocol. In separate experiments, the HAECs were transfected with a miR-146a mimic before determining ROS production.

2.5. Inflammatory Cytokine Expression

HAECs were plated onto coverslips in a 24-well plate at a density of 5 × 105 cells/well and stimulated with thrombin and/or HG. After treatment, the supernatants were collected and separated by centrifugation at 500 ×g for 5 min at 4°C and stored at −80°C until used for analysis. A panel of cytokines including IL-8, IL-1β, IL-6, IL-10, TNF-, and IL-12p70 was simultaneously examined using the Human Inflammatory Cytokines Kit (BD Biosciences Pharmingen, San Diego, CA) through flow cytometry (BD FACSCanto system; Becton Dickinson Corp., San Jose, CA), as previously described [15].

2.6. Monocyte Adhesion Assay

In adhesion experiments, THP-1 cells were labeled with calcein acetoxymethyl ester (Calcein-AM; Molecular Probes, OR). The THP-1 cells were stained with the dye at a concentration of 7.5 μM for 30 min immediately preceding the adhesion assay. HAECs were maintained in 12 wells until 90% confluence. The HAECs (105 cells/well) were then treated with thrombin and/or HG for 5 h and incubated with culture medium containing the labeled THP-1 cells (THP-1/HAECs = 7) for 10 min. After incubation, nonadherent THP-1 cells were removed by gentle washing with PBS for 20 s. The adherent THP-1 cells on different thrombin and/or HG-activated ECs were identified and quantified in 10 randomly selected view fields. In separate experiments, the THP-1 adhesion assay was performed after miR-146a mimic transfection.

2.7. miR Extraction and Analysis

The protocols for miR extraction and determination of miR-146a expression level were previously described [15]. RNU6B expression level served as a loading control.

2.8. Luciferase Reporter Assay

The partial Nox-4 mRNA 3′-UTR containing the miR-146a target site was constructed into a pGL-2-promoter vector (Promega, Madison, WI). HAECs were cotransfected with 1 μg of constructed plasmids and 100 nM of miR-146a mimic or miR-control sequences using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). After 24 h of transfection, cells were harvested to measure luciferase activity according to the manufacturer’s procedures (Promega).

2.9. miR-146a Mimic Transfection

The miR-146a mimic (mirVana miRNA mimic) and miR-control were obtained from Ambion (Austin, TX). HAECs were transfected with hsa-miR-146a mimic (30 nM) or miR-control (30 nM) using the Lipofectamine 2000 transfection reagent (Invitrogen) in serum-free M-199 medium for 2 h. After transfection, the M-199 medium was changed to the endothelial cell growth medium. HAECs were then treated with thrombin and HG for different times in the respective experiments. After treatment, the supernatants were collected and preserved for studies of inflammatory cytokine expression. The HAECs were collected, and the expression levels of Nox4, VCAM-1, ICAM-1, SELE, IL6, IL8 mRNA, Nox4 protein, and ROS activity were determined. In addition, THP-1 adhesion experiments were performed after miR-146a mimic transfection.

2.10. Statistical Analysis

Statistical analyses were performed using SPSS 12.0 statistical software for Windows (SPSS Inc., Chicago, IL). All data are presented as the mean ± SEM. The significance between 2 groups was determined using unpaired -tests. values less than 0.05 were considered statistically significant.

3. Results

3.1. Endothelial Nox4 and Intracellular ROS Were Significantly Induced by HG/Thrombin

We first examined the effects of HG and thrombin on the expression of endothelial Nox1, Nox2, Nox4, and Nox5 mRNA expression (Figure 1(a)). After 5 h of stimulation, high D-glucose (HG, 25 mmol/L) alone caused significant 1.95- and 2.74-fold increases in Nox1 and Nox4 mRNA expression, respectively, while the Nox2 and Nox5 mRNA expression did not change. Thrombin (2 U/mL) alone caused a significant 3.67-fold increase in Nox5 mRNA expression, while Nox1, Nox2, and Nox4 mRNA expression did not change. HG/thrombin cotreatment caused significant 3.62- and 10.69-fold increases in Nox1 and Nox4 mRNA, respectively, while Nox2 and Nox5 expression did not change. Both L-glucose treatment and L-glucose/thrombin cotreatment had no discernible effects on the mRNA expression of Nox1, Nox2, Nox4, and Nox5.

In the western blot analysis, HG/thrombin cotreatment for 12 h caused a significant 1.33-fold increase in Nox4 expression compared with the control, while the L-glucose treatment and L-glucose/thrombin cotreatment had no discernible effects on the protein expression of Nox4 (Figure 1(b)). To determine if HG/thrombin-induced Nox4 expression was associated with enhanced intracellular ROS production, DCFH-DA assay was employed. As shown in Figure 1(c), HG and thrombin treatment alone for 5 h caused significant 1.48- and 2.40-fold increases of ROS production in HAECs, respectively. HG/thrombin cotreatment further increased the ROS production up to 2.81-fold.

3.2. Endothelial Inflammation Was Significantly Induced by HG/Thrombin

HG/thrombin-induced inflammatory cytokine changes were first examined using the Human Inflammatory Cytokines Kit. The HG/thrombin cotreatment for 12 h caused an increase in the IL-8 and IL-6 levels in the conditioned medium, as shown by the rightward shift of the dotted lines; however, IL-1β, IL-10, TNF-, and IL-12p70 expression levels were not affected (Figure 2(a)). In addition, HG/thrombin cotreatment caused 4.06-fold and 5.05-fold increases of IL-6 and IL-8 mRNA gene expression levels, respectively (Figure 2(b)).

The adhesion of circulating monocytes to endothelial cells is an important event in causing vascular inflammation and atherosclerosis development [22]. As shown in Figure 2(b), HG/thrombin cotreatment significantly increased monocytic THP-1 cell adhesion to HAECs. While HG and thrombin treatment alone for 5 h caused 2.84- and 2.15-fold increases in the THP-1 adhesion to HAECs, respectively, HG/thrombin cotreatment caused an 11.43-fold synergistic increase of THP-1 adhesion (Figure 2(c)). The increased THP-1 adhesiveness was associated with increased gene expression of cellular adhesion molecules (CAMs). HG/thrombin cotreatment caused 8.72-fold, 11.67-fold, and 67.21-fold increases of VCAM-1, ICAM-1, and SELE mRNA gene expression levels, respectively (Figure 2(d)). These data demonstrate that increased expression of these CAMs was at least partially responsible for increased THP-1 adhesiveness in HG/thrombin-activated HAECs.

Oxidative stress is known to impair endothelial function. Therefore, we tested whether ROS are involved in the HG/thrombin-induced endothelial inflammation. As shown in Figure 2(e), an ROS scavenger N-acetylcysteine (NAC, 5 mM) pretreatment caused a significant decrease in the gene expression of VCAM-1, ICAM-1, and SELE, suggesting that ROS are involved in the HG/thrombin-induced endothelial inflammation.

3.3. Nox4 Is a Direct Target of miR-146a

Bioinformatic miR target analysis using miR databases ( identified homology between miR-146a and the 3′-UTR of the human Nox4 mRNA, indicating that Nox4 is a potential miR-146a target (Figure 3(a)). To investigate whether miR-146a can interact with Nox4 mRNA 3′-UTR, a luciferase reporter assay was performed. As shown in Figure 3(b), cotransfection of pGL2-Nox4-3′-UTR and the miR-146a mimic resulted in a decrease in luciferase signal to 47% of that in the miR-control, which confirmed direct binding of miR-146a to the Nox4 3′-UTR.

3.4. HG/Thrombin Downregulated miR-146a Expression

Since miR-146a is an important diabetes-associated posttranscriptional regulator, we determined whether miR-146a levels changed in HG/thrombin-stimulated HAECs. As shown in Figure 4, treatment with either HG or thrombin separately for 5 h significantly decreased miR-146a expression to 83% and 76% of that in the control, respectively. HG/thrombin cotreatment further downregulated the miR-146a expression to 58% of that in the control. In contrast, both L-glucose treatment and L-glucose/thrombin cotreatment had no discernible effects on the expression of miR-146a. These findings indicate that the anti-inflammatory feedback circuit mediated by cellular miR-146a levels was impaired in the HG/thrombin-activated HAECs.

3.5. Nox4 Expression and Intracellular ROS Production Were Attenuated in miR-146 Mimic-Transfected, HG/Thrombin-Treated HAECs

To determine whether miR-146a can inhibit Nox4 expression in the HG/thrombin-stimulated HAECs, we transfected HAECs with a miR-146a mimic. Regarding Nox4 mRNA expression, the stimulatory effect of HG/thrombin was preserved in the miR-control-transfected, HG/thrombin-stimulated HAECs. In contrast, the miR-146a mimic abolished the stimulatory effect of Nox4 mRNA expression in HG/thrombin-stimulated HAECs (Figure 5(a)). Regarding Nox4 protein expression, the stimulatory effect of HG/thrombin on Nox4 protein expression was also attenuated in miR-146a mimic-transfected HAECs (Figure 5(b)). This inhibitory effect of the miR-146 mimic on the Nox4 expression concurrently occurred with decreased ROS production in the HG/thrombin-stimulated HAECs (Figure 5(c)).

3.6. Endothelial Inflammation Was Attenuated by the miR-146 Mimic

To further determine whether the reduced Nox4 expression and ROS production were associated with reduced endothelial inflammation in the miR-146 mimic-transfected, HG/thrombin-stimulated HAECs, we measured inflammatory cytokine expression, THP-1 adhesion, and inflammatory gene expression. As anticipated, both IL-8 and IL-6 protein expression in the conditioned medium were attenuated by miR-146a mimic transfection (Figure 6(a)). Furthermore, the adhesion of THP-1 cells (Figure 6(b)) and gene expression of VACM-1, ICAM-1, SELE, IL-6, and IL-8 (Figure 6(c)) were also significantly reduced in the miR-146a transfected, HG/thrombin-stimulated HAECs.

The proposed role of miR-146a in regulating HG/thrombin-induced endothelial inflammation is shown in Figure 7.

4. Discussion

This study demonstrated that HG/thrombin exerts a synergistic effect to upregulate Nox4 mRNA expression, Nox4 protein expression and to increase ROS generation in HAECs. Such diabetes-associated stimuli also downregulate endothelial miR-146a cellular level and enhance endothelial inflammatory phenotypes. The luciferase reporter assay and transfection experiments confirm the role of miR-146a in the posttranscriptional regulation of Nox4 expression. Furthermore, overexpression of the miR-146a mimic can result in a vascular protective effect by its anti-inflammatory effect in HG/thrombin-stimulated HAECs. Such properties of miR-146a may be useful for treating accelerated atherosclerosis and atherothrombosis in diabetes.

Blood vessels expressed a high level of Nox4 [4]. Additionally, gene expression studies reported that Nox4 was the dominant isoform expressed in endothelial cells [23, 24]. In endothelial cells, multiple cellular stresses, including oscillatory shear stress [25], TNF- [26], lipopolysaccharide [27], oxidized-phospholipids [28], and glycated albumin [29], were reported to upregulate endothelial Nox4 expression. The upregulated Nox4, in turn, mediated multiple detrimental effects on endothelial cells, including senescence [30], apoptosis [31], and proinflammatory response [27]. Elevated Nox4 expression was previously reported in many cardiovascular diseases including atherosclerosis, pulmonary artery hypertension, stroke, and heart failure [32]. In addition, Nox4 plays a critical role in mediating diabetic nephropathy [33] and diabetic retinopathy [34]. Our data provide evidence that Nox4 expression, ROS production, and endothelial inflammation were strongly upregulated in the HG/thrombin-stimulated HAECs, further supporting Nox4-mediated vascular complications in diabetes. Interestingly, although the L-glucose alone did not change endothelial Nox4 expression, it did cause reduction of thrombin-induced Nox5 mRNA expression and ROS production. Valeri et al. reported that both fructose and D-tagatose (L-epimer of D-fructose) had cytoprotective effects in prooxidant (i.e., cocaine or nitrofurantoin) induced rat hepatocyte cell injury; these effects were exerted by suppressing the iron-catalyzed formation of ROS [35]. Moreover, Paterna et al. also showed that D-tagatose prevented oxidative cell injury induced by nitrofurantoin or toxic iron overload with ferric nitrilotriacetate in mouse hepatocytes [36]. Their findings revealed that other monosaccharides might have a role in attenuating oxidative cell injury, although additional studies are needed to address the role of L-glucose in alleviating ROS production.

Nox4 activity is constitutive for its ROS-generating ability [37]. The close correlation between ROS generation and Nox4 mRNA level indicates that Nox4 is an inducible isoform [38]. As shown in our data, the amount of ROS production and the degree of Nox4 mRNA upregulation indicate that increased ROS production in HG/thrombin-stimulated HAECs was at least partially dependent on Nox4 upregulation. ROS are important signaling molecules that participate in endothelial inflammation [39]. Previous studies reported that Nox4 played an important role in mediating IL-8 expression [27] and THP-1 adhesion [40, 41]. Consistent with these findings, we observed attenuated ROS production and endothelial inflammation after downregulation of Nox4 expression with a miR-146a mimic, indicating that Nox4-inducing ROS were partially responsible for the proinflammatory response in HG/thrombin-stimulated HAECs.

Nox4 is mostly regulated by transcription via several transcription factors, including E2F, NFκB, STAT1/3, HIF-1, Nrf2, and Oct-1 [42]. The posttranscriptional regulation of Nox4, however, is less well understood. Interestingly, 2 separate groups reported that Nox4 was regulated at the posttranscriptional level by miR-25. In the first study, Fu et al. reported that miR-25 was significantly reduced in HG-treated rat mesangial cells and the kidneys of streptozotocin-induced diabetic rats. These researchers demonstrated that miR-25 was a direct target of Nox4 3′-UTR and concluded that miR-25 may contribute to the regulation of Nox4 expression in diabetic nephropathy [43]. In the second group, Varga et al. demonstrated that miR-25 was downregulated in the heart of cholesterol-enriched diet-induced hypercholesterolemia rats. These researchers concluded that downregulated miR-25 contributes to myocardial oxidative/nitrative stress through increased Nox4 expression [44]. Similar to the regulation patterns of miR-25, we also noted that HG/thrombin downregulated miR-146a expression and upregulated Nox4 expression. A luciferase reporter assay confirmed that Nox4 3′-UTR is a direct target of miR-146a. In addition, transfection experiments further support that the stimulatory effect of HG/thrombin on Nox4 expression was at least partially mediated by a posttranscriptional regulatory mechanism via cellular miR-146a levels. All of our findings also indicate a role of impaired miR-146a expression in diabetes.

Previous studies have shown that miR-146a negatively modulated IL-6 and IL-8 in human fibroblasts [45] and human trabecular meshwork cells [46]. Our data also showed that the miR-146 mimic downregulated IL-6 and IL-8 expression in HG/thrombin-stimulated HAECs. Increased IL-6 expression and signaling events are known to contribute to both atherosclerotic plaque growth and plaque destabilization [47]. In diabetes, IL-6 was reported as an independent predictor of microvascular complications and cardiovascular disease [48]. On the other hand, IL-8 signaling was important for the angiogenic response and survival of endothelial cells [49]. Angiogenesis in atherosclerotic plaques is important for plaque development and plaque vulnerability [50]. Increased IL-8 levels are also reported to predict cardiovascular events in patients with stable coronary artery disease [51]. Our data demonstrate that both IL-6/IL-8 expression and THP-1 adhesion were strongly upregulated by HG/thrombin, indicating that diabetic plaque rupture with thrombin generation in a hyperglycemic medium can exert a vicious autoamplifying cycle by further accelerating vascular inflammation and atherosclerosis development.

CAMs (VCAM-1, ICAM-1, and SELE) are important for macrophage recruitment, endothelial inflammation, and subsequent atherosclerotic plaque development [22]. By activating the HAECs with HG/thrombin, we observed increased expression of these CAMs, while the miR-146a mimic attenuated expression of these CAMs and associated THP-1 adhesiveness. Interestingly, Wu et al. reported that aerobic exercise and statins could increase miR-146a levels in ApoE-null mice, thereby attenuating vascular inflammation through reducing TLR4 and TRAF6 signaling [52]. Our previous work also found that angiotensin-(1–7) can decrease endothelial IL-6 expression in glycated albumin-stimulated HAECs through its ability to enhance endogenous miR-146a levels [15]. All of these findings supported the beneficial effects of modulating miR-146a in atherosclerosis and diabetes-associated vascular injury.

5. Conclusions

HG/thrombin causes impairment of miR-146a expression with an increase of Nox4 expression, ROS production, and inflammatory phenotypes in HAECs. In contrast, the miR-146a mimic exerts an endothelial protective effect by attenuating Nox4 expression, ROS production, and endothelial inflammation. These findings indicate therapeutic potential of modulating miR-146a in alleviating diabetic vascular complications.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.


This study was supported by the Research Laboratory of Pediatrics, Children’s Hospital, China Medical University, and by a Grant from China Medical University Hospital (DMR-103-004).


  1. R. Puri, Y. Kataoka, K. Uno, and S. J. Nicholls, “The distinctive nature of atherosclerotic vascular disease in diabetes: pathophysiological and morphological insights,” Current Diabetes Reports, vol. 12, no. 3, pp. 280–285, 2012. View at: Publisher Site | Google Scholar
  2. C. M. Sena, A. M. Pereira, and R. Seica, “Endothelial dysfunction—a major mediator of diabetic vascular disease,” Biochim Biophys Acta, vol. 1832, no. 12, pp. 2216–2231, 2013. View at: Google Scholar
  3. F. Paneni, J. A. Beckman, M. A. Creager, and F. Cosentino, “Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I,” European Heart Journal, vol. 34, no. 31, pp. 2436–2443, 2013. View at: Publisher Site | Google Scholar
  4. K. Bedard and K.-H. Krause, “The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology,” Physiological Reviews, vol. 87, no. 1, pp. 245–313, 2007. View at: Publisher Site | Google Scholar
  5. T. Marin, B. Gongol, Z. Chen et al., “Mechanosensitive microRNAs-role in endothelial responses to shear stress and redox state,” Free Radical Biology and Medicine, vol. 64, pp. 61–68, 2013. View at: Publisher Site | Google Scholar
  6. K. D. Taganov, M. P. Boldin, K.-J. Chang, and D. Baltimore, “NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 33, pp. 12481–12486, 2006. View at: Publisher Site | Google Scholar
  7. J. Hou, P. Wang, L. Lin et al., “MicroRNA-146a feedback inhibits RIG-I-dependent type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2,” Journal of Immunology, vol. 183, no. 3, pp. 2150–2158, 2009. View at: Publisher Site | Google Scholar
  8. N. Li, X. Xu, B. Xiao et al., “H. pylori related proinflammatory cytokines contribute to the induction of miR-146a in human gastric epithelial cells,” Molecular Biology Reports, vol. 39, no. 4, pp. 4655–4661, 2012. View at: Publisher Site | Google Scholar
  9. T. Chen, Z. Li, W. Zhu et al., “MicroRNA-146a regulates the maturation process and pro-inflammatory cytokine secretion by targeting CD40L in oxLDL-stimulated dendritic cells,” FEBS Letters, vol. 585, no. 3, pp. 567–573, 2011. View at: Publisher Site | Google Scholar
  10. H. S. Cheng, N. Sivachandran, A. Lau et al., “MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways,” EMBO Molecular Medicine, vol. 5, no. 7, pp. 949–966, 2013. View at: Publisher Site | Google Scholar
  11. C.-H. Hsieh, C.-S. Rau, S.-F. Jeng et al., “Identification of the potential target genes of microRNA-146a induced by PMA treatment in human microvascular endothelial cells,” Experimental Cell Research, vol. 316, no. 7, pp. 1119–1126, 2010. View at: Publisher Site | Google Scholar
  12. B. Feng, S. Chen, K. McArthur et al., “miR-146a-mediated extracellular matrix protein production in chronic diabetes complications,” Diabetes, vol. 60, no. 11, pp. 2975–2984, 2011. View at: Publisher Site | Google Scholar
  13. D. S. Karolina, A. Armugam, S. Tavintharan et al., “MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus,” PLoS ONE, vol. 6, no. 8, Article ID e22839, 2011. View at: Publisher Site | Google Scholar
  14. J. Xu, W. Wu, L. Zhang et al., “The role of MicroRNA-146a in the pathogenesis of the diabetic wound-healing impairment: correction with mesenchymal stem cell treatment,” Diabetes, vol. 61, no. 11, pp. 2906–2912, 2012. View at: Publisher Site | Google Scholar
  15. H.-J. Wang, W.-Y. Lo, and L.-J. Lin, “Angiotensin-(1–7) decreases glycated albumin-induced endothelial interleukin-6 expression via modulation of miR-146a,” Biochemical and Biophysical Research Communications, vol. 430, no. 3, pp. 1157–1163, 2013. View at: Publisher Site | Google Scholar
  16. M. Balasubramanyam, S. Aravind, K. Gokulakrishnan et al., “Impaired miR-146a expression links subclinical inflammation and insulin resistance in Type 2 diabetes,” Molecular and Cellular Biochemistry, vol. 351, no. 1-2, pp. 197–205, 2011. View at: Publisher Site | Google Scholar
  17. G. Boden, V. R. Vaidyula, C. Homko, P. Cheung, and A. K. Rao, “Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 11, pp. 4352–4358, 2007. View at: Publisher Site | Google Scholar
  18. L. Ay, F. Hoellerl, C. Ay et al., “Thrombin generation in type 2 diabetes with albuminuria and macrovascular disease,” European Journal of Clinical Investigation, vol. 42, no. 5, pp. 470–477, 2012. View at: Publisher Site | Google Scholar
  19. T. Inoguchi, T. Sonta, H. Tsubouchi et al., “Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase,” Journal of the American Society of Nephrology, vol. 14, no. 8, supplement 3, pp. S227–S232, 2003. View at: Publisher Site | Google Scholar
  20. J. A. Holland, J. W. Meyer, M.-M. Chang, R. W. O'Donnell, D. K. Johnson, and L. M. Ziegler, “Thrombin stimulated reactive oxygen species production in cultured human endothelial cells,” Endothelium, vol. 6, no. 2, pp. 113–121, 1998. View at: Google Scholar
  21. H.-J. Wang, W.-Y. Lo, T.-L. Lu, and H. Huang, “(-)-Epigallocatechin-3-gallate decreases thrombin/paclitaxel-induced endothelial tissue factor expression via the inhibition of c-Jun terminal NH2 kinase phosphorylation,” Biochemical and Biophysical Research Communications, vol. 391, no. 1, pp. 716–721, 2010. View at: Publisher Site | Google Scholar
  22. P. N. Hopkins, “Molecular biology of atherosclerosis,” Physiological Reviews, vol. 93, no. 3, pp. 1317–1542, 2013. View at: Publisher Site | Google Scholar
  23. J. D. van Buul, M. Fernandez-Borja, E. C. Anthony, and P. L. Hordijk, “Expression and localization of NOX2 and NOX4 in primary human endothelial cells,” Antioxidants and Redox Signaling, vol. 7, no. 3-4, pp. 308–317, 2005. View at: Publisher Site | Google Scholar
  24. T. Ago, T. Kitazono, H. Ooboshi et al., “Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase,” Circulation, vol. 109, no. 2, pp. 227–233, 2004. View at: Publisher Site | Google Scholar
  25. J. Hwang, M. H. Ing, A. Salazar et al., “Pulsatile versus oscillatory shear stress regulates NADPH oxidase subunit expression: implication for native LDL oxidation,” Circulation Research, vol. 93, no. 12, pp. 1225–1232, 2003. View at: Publisher Site | Google Scholar
  26. L. S. Yoshida and S. Tsunawaki, “Expression of NADPH oxidases and enhanced H2O2-generating activity in human coronary artery endothelial cells upon induction with tumor necrosis factor-α,” International Immunopharmacology, vol. 8, no. 10, pp. 1377–1385, 2008. View at: Publisher Site | Google Scholar
  27. H. S. Park, J. N. Chun, H. Y. Jung, C. Choi, and Y. S. Bae, “Role of NADPH oxidase 4 in lipopolysaccharide-induced proinflammatory responses by human aortic endothelial cells,” Cardiovascular Research, vol. 72, no. 3, pp. 447–455, 2006. View at: Publisher Site | Google Scholar
  28. S. Lee, N. M. Gharavi, H. Honda et al., “A role for NADPH oxidase 4 in the activation of vascular endothelial cells by oxidized phospholipids,” Free Radical Biology and Medicine, vol. 47, no. 2, pp. 145–151, 2009. View at: Publisher Site | Google Scholar
  29. B. K. Rodiño-Janeiro, M. González-Peteiro, R. Ucieda-Somoza, J. R. González-Juanatey, and E. Álvarez, “Glycated albumin, a precursor of advanced glycation end-products, up-regulates NADPH oxidase and enhances oxidative stress in human endothelial cells: molecular correlate of diabetic vasculopathy,” Diabetes/Metabolism Research and Reviews, vol. 26, no. 7, pp. 550–558, 2010. View at: Publisher Site | Google Scholar
  30. M. Vasa-Nicotera, H. Chen, P. Tucci et al., “MiR-146a is modulated in human endothelial cell with aging,” Atherosclerosis, vol. 217, no. 2, pp. 326–330, 2011. View at: Publisher Site | Google Scholar
  31. S. Basuroy, S. Bhattacharya, C. W. Leffler, and H. Parfenova, “Nox4 NADPH oxidase mediates oxidative stress and apoptosis caused by TNF-α in cerebral vascular endothelial cells,” The American Journal of Physiology—Cell Physiology, vol. 296, no. 3, pp. C422–C432, 2009. View at: Publisher Site | Google Scholar
  32. F. Chen, S. Haigh, S. Barman, and D. J. R. Fulton, “From form to function: the role of Nox4 in the cardiovascular system,” Frontiers in Physiology, vol. 3, p. 412, 2012. View at: Publisher Site | Google Scholar
  33. M. Sedeek, G. Callera, A. Montezano et al., “Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy,” American Journal of Physiology—Renal Physiology, vol. 299, no. 6, pp. F1348–F1358, 2010. View at: Publisher Site | Google Scholar
  34. J. Li, J. J. Wang, Q. Yu, K. Chen, K. Mahadev, and S. X. Zhang, “Inhibition of reactive oxygen species by lovastatin downregulates vascular endothelial growth factor expression and ameliorates blood-retinal barrier breakdown in db/db mice: role of NADPH oxidase 4,” Diabetes, vol. 59, no. 6, pp. 1528–1538, 2010. View at: Publisher Site | Google Scholar
  35. F. Valeri, F. Boess, A. Wolf, C. Göldlin, and U. A. Boelsterli, “Fructose and tagatose protect against oxidative cell injury by iron chelation,” Free Radical Biology and Medicine, vol. 22, no. 1-2, pp. 257–268, 1996. View at: Publisher Site | Google Scholar
  36. J. C. Paterna, F. Boess, A. Stäubli, and U. A. Boelsterli, “Antioxidant and cytoprotective properties of D-tagatose in cultured murine hepatocytes,” Toxicology and Applied Pharmacology, vol. 148, no. 1, pp. 117–125, 1998. View at: Publisher Site | Google Scholar
  37. A. C. Montezano, D. Burger, G. S. Ceravolo, H. Yusuf, M. Montero, and R. M. Touyz, “Novel nox homologues in the vasculature: focusing on Nox4 and Nox5,” Clinical Science, vol. 120, no. 4, pp. 131–141, 2011. View at: Publisher Site | Google Scholar
  38. L. Serrander, L. Cartier, K. Bedard et al., “NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation,” Biochemical Journal, vol. 406, no. 1, pp. 105–114, 2007. View at: Publisher Site | Google Scholar
  39. K. K. Griendling, D. Sorescu, B. Lassègue, and M. Ushio-Fukai, “Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 10, pp. 2175–2183, 2000. View at: Publisher Site | Google Scholar
  40. C. R. Williams, X. Lu, R. L. Sutliff, and C. Michael Hart, “Rosiglitazone attenuates NF-κB-mediated Nox4 upregulation in hyperglycemia-activated endothelial cells,” American Journal of Physiology - Cell Physiology, vol. 303, no. 2, pp. C213–C223, 2012. View at: Publisher Site | Google Scholar
  41. C. F. Lee, S. Ullevig, H. S. Kim, and R. Asmis, “Regulation of monocyte adhesion and migration by Nox4,” PLoS ONE, vol. 8, no. 6, Article ID e66964, 2013. View at: Publisher Site | Google Scholar
  42. B. Lassègue, A. San Martín, and K. K. Griendling, “Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system,” Circulation Research, vol. 110, no. 10, pp. 1364–1390, 2012. View at: Publisher Site | Google Scholar
  43. Y. Fu, Y. Zhang, Z. Wang et al., “Regulation of NADPH oxidase activity is associated with miRNA-25-mediated NOX4 expression in experimental diabetic nephropathy,” The American Journal of Nephrology, vol. 32, no. 6, pp. 581–589, 2010. View at: Publisher Site | Google Scholar
  44. Z. V. Varga, K. Kupai, G. Szucs et al., “MicroRNA-25-dependent up-regulation of NADPH oxidase 4 (NOX4) mediates hypercholesterolemia-induced oxidative/nitrative stress and subsequent dysfunction in the heart,” Journal of Molecular and Cellular Cardiology, vol. 62, pp. 111–121, 2013. View at: Publisher Site | Google Scholar
  45. D. Bhaumik, G. K. Scott, S. Schokrpur et al., “MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8.,” Aging, vol. 1, no. 4, pp. 402–411, 2009. View at: Google Scholar
  46. G. Li, C. Luna, J. Qiu, D. L. Epstein, and P. Gonzalez, “Modulation of inflammatory markers by miR-146a during replicative senescence in trabecular meshwork cells,” Investigative Ophthalmology and Visual Science, vol. 51, no. 6, pp. 2976–2985, 2010. View at: Publisher Site | Google Scholar
  47. H. Schuett, M. Luchtefeld, C. Grothusen, K. Grote, and B. Schieffer, “How much is too much? Interleukin-6 and its signalling in atherosclerosis,” Thrombosis and Haemostasis, vol. 102, no. 2, pp. 215–222, 2009. View at: Publisher Site | Google Scholar
  48. M. T. Schram, N. Chaturvedi, C. G. Schalkwijk, J. H. Fuller, and C. D. A. Stehouwer, “Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes—the EURODIAB Prospective Complications Study,” Diabetologia, vol. 48, no. 2, pp. 370–378, 2005. View at: Publisher Site | Google Scholar
  49. D. J. Waugh and C. Wilson, “The interleukin-8 pathway in cancer,” Clinical Cancer Research, vol. 14, no. 21, pp. 6735–6741, 2008. View at: Publisher Site | Google Scholar
  50. J. C. Sluimer and M. J. Daemen, “Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis,” Journal of Pathology, vol. 218, no. 1, pp. 7–29, 2009. View at: Publisher Site | Google Scholar
  51. T. Inoue, H. Komoda, M. Nonaka, M. Kameda, T. Uchida, and K. Node, “Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease,” International Journal of Cardiology, vol. 124, no. 3, pp. 319–325, 2008. View at: Publisher Site | Google Scholar
  52. X. D. Wu, K. Zeng, W. L. Liu et al., “Effect of aerobic exercise on miRNA-TLR4 signaling in atherosclerosis,” International Journal of Sports Medicine, vol. 35, no. 4, pp. 344–350, 2014. View at: Google Scholar

Copyright © 2014 Huang-Joe Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.